Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:04 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effects of Anti-Glaucoma Medications on the Ocular Surface
NCT01315574 · Massachusetts Eye and Ear Infirmary · PHASE4 · terminated · last registry update 2017-03-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow Enrollment” | – | Registry record, Massachusetts Eye and Ear Infirmary |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGFR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-02-15Results posted on the registry: Inotek Pharmaceuticals Corporation, trabodenoson 6.0% / latanoprost 0.005% QD + trabodenoson 3.0% / latanoprost 0.005% QD (NCT02829996)
- 2018-02-14Results posted on the registry: University of Nebraska, Latanoprost + Dorzolamide (NCT00572936)
- 2018-02-05Phase 3 first posted: Taejoon Pharmaceutical Co., Ltd., TJO-002 + Latanoprost (NCT03419975)
- 2018-01-19Also stopped (withdrawn): Johns Hopkins University, a drug against PTGFR (NCT03274323)
- 2017-09-15Phase 3 first posted: Aerie Pharmaceuticals, Netarsudil/Latanoprost 0.02%/0.005% + GANFORT® (NCT03284853)
- 2017-09-13Results posted on the registry: University of Michigan, Variation in eye pressure response to timolol and latanoprost treatment (NCT01677507)
- 2017-07-25Also stopped (terminated): CHU de Quebec-Universite Laval, Generic latanoprost + Brand-name latanoprost (NCT02047630)
- 2017-06-29Results posted on the registry: Brigham and Women's Hospital, Oxytocin Infusion + Oxytocin Bolus (NCT01549223)
- 2017-03-17Also stopped (terminated): Allergan, Bimatoprost (NCT02676310)
- 2017-01-23Results posted on the registry: Laboratoires Thea, T2347 + Xalacom (NCT02278614)
- 2016-12-05Phase 3 first posted: Santen Pharmaceutical Co., Ltd., DE-117 + Latanoprost ophthalmic solution (NCT02981446)
- 2016-09-26Phase 3 first posted: Ocular Therapeutix, Inc., Travoprost (NCT02914509)
- 2016-08-08Results posted on the registry: Alcon Research, Beta-blocker monotherapy + Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (NCT02003391)
- 2016-07-28Results posted on the registry: Université de Montréal, placebo + travoprost (NCT01711177)
- 2016-07-04Phase 3 first posted: Santen Pharmaceutical Co., Ltd., DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005% (NCT02822742)
- 2016-06-16Phase 3 first posted: Laboratorios Sophia S.A de C.V., PRO-067 + GAAP Ofteno® (NCT02801617)
- 2016-06-16Results posted on the registry: Allergan, onabotulinumtoxinA + bimatoprost ophthalmic solution 0.03% (NCT02176356)
- 2016-05-30Results posted on the registry: Sun Pharma Advanced Research Company Limited, SPARC0912 + Reference0912 (NCT00947661)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision